Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

China · Delayed Price · Currency is CNY

39.59

+0.69 (1.77%)

Oct 14, 2026, 11:04 AM CST

Market Cap	5.79B -5.4%
Revenue (ttm)	459.42M -7.3%
Net Income	20.30M -81.5%
EPS	0.15 -77.2%
Shares Out	146.32M
PE Ratio	252.03
Forward PE	n/a
Dividend	0.70 (1.77%)
Ex-Dividend Date	Jun 1, 2026

Volume	1,379,666
Open	38.73
Previous Close	38.90
Day's Range	38.41 - 40.19
52-Week Range	30.40 - 50.98
Beta	0.66
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Hangzhou Biotest Biotech

Hangzhou Biotest Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of in vitro diagnostic reagents in China and internationally. The company offers point-of-care testing rapid diagnostic reagents for drug abuse, infectious disease, fertility health, tumor market/oncology, cardiology market, veterinary, inflammation, and other testing. It also provides microfluidic immunofluorescence analysis systems; and Diagpal SE and Diagpal lateral flow readers. In addition, the company enga... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2008

Employees 598

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688767

Full Company Profile

Financial Performance

In 2025, Hangzhou Biotest Biotech's revenue was 448.01 million, a decrease of -19.91% compared to the previous year's 559.40 million. Earnings were 49.25 million, a decrease of -70.94%.

Financial Statements